156.60 +0.05 +0.03%
After-market 07:58:52 PM NYSE
Plus500. 81% of retail CFD accounts lose money
156.55 -1.37 -0.87%
Official Close 04:00:00 PM NYSE
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
Is Johnson & Johnson stock a Buy, Sell or Hold?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 41 buy ratings, 34 hold ratings, and 1 sell ratings.What was the 52-week low for Johnson & Johnson stock?
The low in the last 52 weeks of Johnson & Johnson stock was 144.95. According to the current price, Johnson & Johnson is 108.04% away from the 52-week low.What was the 52-week high for Johnson & Johnson stock?
The high in the last 52 weeks of Johnson & Johnson stock was 175.96. According to the current price, Johnson & Johnson is 89.00% away from the 52-week high.What are analysts forecasts for Johnson & Johnson stock?
The 76 analysts offering price forecasts for Johnson & Johnson have a median target of 185.01, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 84.64 difference from the last price of 156.60.Johnson & Johnson Stock Snapshot
0.00
Bid
0.00
Bid Size
0.00
Ask
2/16/2024
Date
7:58 PM
Time
0.00
Volume
156.55
Prev. Close
156.60
Open
375.36 B
Market Cap
2.41 B
Number of Shares
155.69
Day Low
157.26
Day High
156.60
144.95
52 Week Low
175.96
52 Week High
156.60
4.80
Dividend
3.07
Dividend Yield
15.80
P/E Ratio
99.80
Free Float in %
10.66
EPS 2024
33.74
Book Value per Share
11.23
Cash Flow per Share
Johnson & Johnson NewsMore News
InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
InvestorPlace
7 Small-Cap Stocks With Significant Upside Potential in 2024
TipRanks
Historical Prices for Johnson & Johnson
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Johnson & Johnson Analyst Data
Total Analysts: 76
Buy Ratings: 41 Neutral Ratings: 34 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 40.00 Median: 185.01 Highest: 215.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Johnson & Johnson Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 02/06/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/24/24 | Morgan Stanley | Maintained Hold | $169 | neutral | ||
| 01/24/24 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 01/23/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/09/24 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $175 | gut | ||
| 12/13/23 | Wells Fargo & Co | Downgraded to Hold | $163 | neutral | ||
| 12/06/23 | RBC Capital Markets | Maintained Buy | $181 | gut | ||
| 12/01/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 12/01/23 | UBS | Upgraded to Buy | $180 | gut | ||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 11/17/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/18/23 | Morgan Stanley | Maintained Hold | $171 | neutral | ||
| 10/18/23 | Raymond James Financial, Inc. | Maintained Buy | $172 | gut | ||
| 10/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/12/23 | Barclays Capital | Maintained Hold | $162 | neutral | ||
| 10/11/23 | Morgan Stanley | Maintained Hold | $174 | neutral | ||
| 10/09/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 10/05/23 | RBC Capital Markets | Maintained Buy | $178 | gut | ||
| 10/02/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/18/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/08/23 | Barclays Capital | Maintained Hold | $158 | neutral | ||
| 09/06/23 | HSBC | Maintained Sell | $175 | schlecht | ||
| 09/05/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 09/05/23 | Raymond James Financial, Inc. | Maintained Buy | $179 | gut | ||
| 08/31/23 | Wells Fargo & Co | Maintained Buy | $186 | gut | ||
| 08/31/23 | Morgan Stanley | Maintained Hold | $172 | neutral | ||
| 08/30/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/22/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 08/04/23 | Atlantic Equities | Maintained Hold | $170 | neutral | ||
| 07/31/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/25/23 | Barclays Capital | Maintained Hold | $175 | neutral | ||
| 07/24/23 | Raymond James Financial, Inc. | Maintained Buy | $184 | gut | ||
| 07/21/23 | J.P. Morgan | Maintained Hold | $180 | neutral | ||
| 07/21/23 | Morgan Stanley | Maintained Hold | $187 | neutral | ||
| 07/21/23 | Credit Suisse | Maintained Hold | $175 | neutral | ||
| 07/13/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 07/11/23 | Morgan Stanley | Maintained Hold | $187 | neutral | ||
| 06/07/23 | Mizuho | Maintained Buy | $40 | gut | ||
| 05/30/23 | Citigroup Corp. | Maintained Buy | $185 | gut | ||
| 04/19/23 | Atlantic Equities | Maintained Hold | $167 | neutral | ||
| 04/19/23 | Morgan Stanley | Maintained Hold | $183 | neutral | ||
| 04/19/23 | Raymond James Financial, Inc. | Maintained Buy | $181 | gut | ||
| 04/10/23 | Morgan Stanley | Maintained Hold | $179 | neutral | ||
| 03/29/23 | UBS | Maintained Hold | $164 | neutral | ||
| 03/01/23 | Guggenheim | Maintained Hold | $161 | neutral | ||
| 02/01/23 | Cantor Fitzgerald | Maintained Buy | $215 | gut | ||
| 01/25/23 | Morgan Stanley | Maintained Hold | $180 | neutral | ||
| 01/25/23 | Atlantic Equities | Maintained Hold | $168 | neutral |
Johnson & Johnson Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 88,398 | 90,811 | - | - | 102,719 |
| Dividend | 4.80 | 5.00 | - | - | 6.44 |
| Dividend Yield (in %) | 3.04 % | 3.17 % | 3.15 % | 3.48 % | 4.08 % |
| EPS | 10.66 | 11.00 | 11.44 | 11.75 | 12.43 |
| P/E Ratio | 14.80 | 14.35 | 13.80 | 13.43 | 12.70 |
| EBIT | 29,152 | 30,156 | 31,300 | 32,143 | 34,346 |
| EBITDA | 33,435 | 34,833 | 36,857 | 38,949 | 38,137 |
| Net Profit | 25,944 | 26,784 | - | 28,187 | 29,771 |
| Net Profit Adjusted | 25,944 | 26,784 | - | 28,187 | 29,771 |
| Pre-Tax Profit | 30,997 | - | - | 33,738 | 35,667 |
| Net Profit (Adjusted) | - | - | 25,233 | 26,575 | 27,528 |
| EPS (Non-GAAP) ex. SOE | 10.68 | 11.21 | 9.49 | - | - |
| EPS (GAAP) | 8.60 | 9.04 | - | 9.68 | 10.03 |
| Gross Income | 65,953 | - | - | 74,264 | 78,118 |
| Cash Flow from Investing | - | - | - | - | -6,280 |
| Cash Flow from Operations | - | - | - | - | 31,654 |
| Cash Flow from Financing | - | - | - | - | -20,244 |
| Cash Flow per Share | 11.23 | 11.72 | 12.47 | - | - |
| Free Cash Flow | 23,872 | 24,525 | 24,996 | 26,410 | 29,358 |
| Free Cash Flow per Share | 10.79 | 9.96 | 9.27 | - | - |
| Book Value per Share | 33.74 | 37.11 | - | 36.05 | 37.59 |
| Net Debt | -2,998 | -10,383 | -14,698 | -31,584 | - |
| Research & Development Exp. | 14,968 | - | 15,717 | - | 17,015 |
| Capital Expenditure | - | 4,073 | - | - | 3,780 |
| Selling, General & Admin. Exp. | - | - | 23,075 | - | 24,935 |
| Shareholder’s Equity | - | - | - | - | 112,208 |
| Total Assets | - | - | - | - | 227,766 |
| Previous Quarter ending 12/31/23 | Current Quarter ending 03/31/24 | Next Quarter ending 06/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 15 | 16 | 16 | 20 | 16 |
| Average Estimate | 2.281 USD | 2.635 USD | 2.728 USD | 10.663 USD | 10.999 USD |
| Year Ago | 2.350 USD | 2.680 USD | 2.800 USD | 9.920 USD | 10.663 USD |
| Publish Date | 1/23/2024 | 4/16/2024 | 7/16/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 15 | 14 | 14 | 18 | 18 |
| Average Estimate | 21,022 USD | 21,457 USD | 22,359 USD | 88,398 USD | 90,811 USD |
| Year Ago | 23,706 USD | 24,746 USD | 25,530 USD | 85,159 USD | 88,398 USD |
| Publish Date | 1/23/2024 | 4/16/2024 | 7/16/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Johnson & Johnson Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Wolk Joseph J | 02/11/2024 | 10,816.00 | 67,883.00 | 157.40 | Sell | No |
| Swanson James D. | 02/11/2024 | 1,695.00 | 14,318.00 | 157.40 | Sell | No |
| Taubert Jennifer L | 02/11/2024 | 13,403.00 | 154,215.00 | 157.40 | Sell | No |
| Schmid Timothy | 02/11/2024 | 2,887.00 | 12,791.00 | 157.40 | Sell | No |
| Forminard Elizabeth | 02/11/2024 | 1,034.00 | 7,925.00 | 157.40 | Sell | No |
| Duato Joaquin | 02/11/2024 | 15,900.00 | 361,339.00 | 157.40 | Sell | No |
| Wengel Kathryn E | 02/11/2024 | 7,066.00 | 81,947.87 | 157.40 | Sell | No |
| Fasolo Peter | 02/11/2024 | 7,019.00 | 111,625.00 | 157.40 | Sell | No |
| Broadhurst Vanessa | 02/11/2024 | 2,136.00 | 23,735.00 | 157.40 | Sell | No |
| Hait William | 02/11/2024 | 4,076.00 | 38,240.00 | 157.40 | Sell | No |
| Decker Robert J | 02/11/2024 | 523.00 | 18,746.00 | 157.40 | Sell | No |
| Wolk Joseph J | 02/11/2024 | 3,716.00 | 78,699.00 | n/a | Buy | No |
| Wolk Joseph J | 02/11/2024 | 22,119.00 | 74,983.00 | n/a | Buy | No |
| Swanson James D. | 02/11/2024 | 785.00 | 16,013.00 | n/a | Buy | No |
| Swanson James D. | 02/11/2024 | 4,671.00 | 15,228.00 | n/a | Buy | No |
| Taubert Jennifer L | 02/11/2024 | 3,769.00 | 167,618.00 | n/a | Buy | No |
| Taubert Jennifer L | 02/11/2024 | 22,433.00 | 163,849.00 | n/a | Buy | No |
| Schmid Timothy | 02/11/2024 | 825.00 | 15,678.00 | n/a | Buy | No |
| Schmid Timothy | 02/11/2024 | 4,911.00 | 14,853.00 | n/a | Buy | No |
| Forminard Elizabeth | 02/11/2024 | 411.00 | 8,959.00 | n/a | Buy | No |
| Forminard Elizabeth | 02/11/2024 | 2,448.00 | 8,548.00 | n/a | Buy | No |
| Duato Joaquin | 02/11/2024 | 5,267.00 | 377,239.00 | n/a | Buy | No |
| Duato Joaquin | 02/11/2024 | 31,351.00 | 371,972.00 | n/a | Buy | No |
| Wengel Kathryn E | 02/11/2024 | 1,987.00 | 89,013.87 | n/a | Buy | No |
| Wengel Kathryn E | 02/11/2024 | 11,826.00 | 87,026.87 | n/a | Buy | No |
Johnson & Johnson Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Johnson & Johnson | 4.70 | 3.00 | USD |
| 2022 | Johnson & Johnson | 4.45 | 2.52 | USD |
| 2021 | Johnson & Johnson | 4.19 | 2.45 | USD |
| 2020 | Johnson & Johnson | 3.98 | 2.53 | USD |
| 2019 | Johnson & Johnson | 3.75 | 2.57 | USD |
| 2018 | Johnson & Johnson | 3.54 | 2.78 | USD |
| 2017 | Johnson & Johnson | 3.32 | 2.38 | USD |
| 2016 | Johnson & Johnson | 3.15 | 2.73 | USD |
| 2015 | Johnson & Johnson | 2.95 | 2.87 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.63 | USD |
| 2014 | Johnson & Johnson | 2.76 | 2.64 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.80 | USD |
| 2013 | Johnson & Johnson | 2.59 | 2.83 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.45 | USD |
| 2012 | Johnson & Johnson | 2.40 | 3.42 | USD |
| 2011 | Johnson & Johnson | 2.25 | 3.43 | USD |
| 2010 | Johnson & Johnson | 2.11 | 3.41 | USD |
| 2009 | Johnson & Johnson | 1.93 | 3.00 | USD |
| 2008 | Johnson & Johnson | 1.79 | 3.06 | USD |
| 2007 | Johnson & Johnson | 1.62 | 2.43 | USD |
| 2006 | Johnson & Johnson | 1.46 | 2.21 | USD |
| 2005 | Johnson & Johnson | 1.27 | 2.11 | USD |
| 2004 | Johnson & Johnson | 1.09 | 1.72 | USD |
| 2003 | Johnson & Johnson | 0.92 | 1.82 | USD |
| 2002 | Johnson & Johnson | 0.79 | 1.47 | USD |
| 2001 | Johnson & Johnson | 0.70 | 1.17 | USD |
| 2000 | Johnson & Johnson | 0.62 | 1.18 | USD |
| 1999 | Johnson & Johnson | 0.55 | 1.18 | USD |
*Yield of the Respective Date
Johnson & Johnson Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.635 USD | Q1 2024 Earnings Release | 04/16/2024 |
| Earnings Report | 2.728 USD | Q2 2024 Earnings Release | 07/16/2024 |
| Earnings Report | - | Q3 2024 Earnings Release | 10/15/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 01/28/2025 |
Johnson & Johnson Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 2.290 USD | Q4 2023 Earnings Release | 01/23/2024 |
| Press Conference | - | - | 01/23/2024 |
| Press Conference | - | - | 10/17/2023 |
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. .
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
Johnson & Johnson Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.80 |
| The Vanguard Group, Inc. | 9.53 |
| Vanguard Group, Inc. (Subfiler) | 9.11 |
| SSgA Funds Management, Inc. | 5.52 |
| State Street Corp. | 5.52 |
| Vanguard Total Stock Market ETF | 3.14 |
| BlackRock Fund Advisors | 2.89 |
| Vanguard 500 Index Fund | 2.47 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 2.13 |
| State Farm Investment Management Corp. | 1.32 |
| Capital Research & Management Co. (International Investors) | 1.20 |
| SPDR S&P 500 ETF Trust | 1.19 |
| Fidelity 500 Index Fund | 1.18 |
| Norges Bank (13F) | 1.08 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Johnson & Johnson Management
| Name | Job |
|---|---|
| Joaquin Duato | Chairman & Chief Executive Officer |
| Ronald A. Kapusta | Chief Accounting Officer & Controller |
| Robert J. Decker | Chief Accounting Officer & Controller |
| Frederic H. Moll | Chief Development Officer |
| Joseph J. Wolk | Chief Financial Officer & Executive Vice President |
| Paul Ruh | Chief Financial Officer-Consumer Health |
| Peter M. Fasolo | Chief Human Resources Officer & Executive VP |
| Bernardo Tavares | Chief Information Officer |
| Kathryn E. Wengel | Chief Technical Operations & Risk Officer |
| Scott White | Company Group Chairman |
| Eugene A. Woods | Director |
| Jonathan Sheh | Director-Workplace Experience |
| Jennifer L. Taubert | EVP & Worldwide Chairman-Pharmaceuticals |
| Elizabeth Forminard | Executive Vice President & General Counsel |
| James D. Swanson | Global Chief Information Officer & Executive VP |
| Michael Bzdak | Global Dir-Employee Engagement-Global Cmnty Impact |
| George Davy | Global HR Director |
| Caroline Tillett | Global Head-Consumer Health |
| Ahmet Tezel | Global Head-Research & Development |
| Kathleen M. Widmer | Group Chairman-Consumer North America |
| Neil Ackerman | Head-Innovation, Global Supply & Transformation |
| Jennifer A. Doudna | Independent Director |
| Mary C. Beckerle | Independent Director |
| Nadja Y. West | Independent Director |
| A. Eugene Washington | Independent Director |
| Hubert Joly | Independent Director |
| Marillyn A. Hewson | Independent Director |
| D. Scott Davis | Independent Director |
| Mark Alan Weinberger | Independent Director |
| Paula A. Johnson | Independent Director |
| Mark B. McClellan | Independent Director |
| Darius Adamczyk | Independent Director |
| Anne M. Mulcahy | Lead Independent Director |
| Warren Foust | President-Surgical Vision |
| Marc Larkins | Secretary |
| Thomas J. Spellman | Secretary |
| Lisa Romanko | Senior Director-Investor Relations |
| Matthew Stuckley | Senior Finance Director |
| Meredith Stevens | Vice President |
| Jessica Moore | Vice President-Investor Relations |
| William E. Cohn | Vice President-Medical Devices |
| Lisa Paley | Vice President-US Sales |
